Israel Englander Biomea Fusion, Inc. Transaction History

Millennium Management LLC

$192 Billion
Q4 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Biomea Fusion, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 20,000 shares of BMEA stock, worth $57,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,000

Previous 120,000 83.33%

Holding current value

$57,800

Previous $1.21 Million 93.65%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$3.88 - $12.41 $5.25 Million - $16.8 Million	-1,354,087 Reduced 98.24%	24,321 $94,000
Q3 2024 Nov 14, 2024	BUY	$4.23 - $10.1 $5.62 Million - $13.4 Million	1,328,392 Added 2655.93%	1,378,408 $13.9 Million
Q2 2024 Aug 14, 2024	SELL	$4.14 - $15.3 $40,451 - $149,496	-9,771 Reduced 16.34%	50,016 $225,000
Q1 2024 May 15, 2024	SELL	$13.92 - $19.5 $1.34 Million - $1.88 Million	-96,280 Reduced 61.69%	59,787 $893,000
Q4 2023 Feb 14, 2024	SELL	$8.37 - $19.8 $1.47 Million - $3.49 Million	-176,107 Reduced 53.02%	156,067 $2.27 Million
Q2 2023 Aug 14, 2023	BUY	$21.66 - $41.8 $977,797 - $1.89 Million	45,143 Added 15.73%	332,174 $7.29 Million
Q1 2023 May 15, 2023	BUY	$6.8 - $32.35 $1.06 Million - $5.04 Million	155,657 Added 118.48%	287,031 $8.9 Million
Q4 2022 Feb 14, 2023	SELL	$6.3 - $11.6 $141,964 - $261,394	-22,534 Reduced 14.64%	131,374 $1.11 Million
Q3 2022 Nov 14, 2022	SELL	$9.51 - $13.61 $848,444 - $1.21 Million	-89,216 Reduced 36.7%	153,908 $1.51 Million

Others Institutions Holding BMEA

# of Institutions

126

Shares Held

17.5M

Call Options Held

1.8M

Put Options Held

1.08M

View Full List

About Biomea Fusion, Inc.

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $84.6M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

More about BMEA

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account